Due to the fact that EGFR mutations are detected in 20%-40% of NSCLC and promote the progression of cancer 5, investigating this pathway and association with EMT in EGFR TKI-resistance in NSCLC has benefits in respect to those previous studies. The gene discussed is EGFR; the disease is cancer.